


Brodimoprim

Chemical Properties

CAS No. :	56518-41-3
Formula:	C ₁₃ H ₁₅ BrN ₄ O ₂
Molecular Weight:	339.19
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Brodimoprim is an inhibitor of dihydrofolate reductase(DHFR). Brodimoprim is also a long-acting broad-spectrum antibacterial agent characterized by a good pharmacokinetic profile.
Targets(IC50)	Antibacterial,DHFR

Solubility Information

Solubility	DMSO: 6.88 mg/mL (20.28 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.95 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.9482 mL	14.741 mL	29.482 mL
5 mM	0.5896 mL	2.9482 mL	5.8964 mL
10 mM	0.2948 mL	1.4741 mL	2.9482 mL
50 mM	0.059 mL	0.2948 mL	0.5896 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

De Campora E, Radici M, Camaioni A. Efficacy and tolerability of brodimoprim in otitis. J Chemother. 1993 Dec;5(6): 529-31.

Scaglione F, et al. Efficacy and tolerability of brodimoprim od versus norfloxacin bid in the treatment of bacterial urinary tract infections. Int J Clin Pharmacol Res. 1995;15(3):121-5.

Caira MR, et al. Relationships between structural and thermal properties of anhydrous and solvated crystalline forms of brodimoprim. J Pharm Sci. 2007 May;96(5):996-1007.

Braga PC, et al. Influence of brodimoprim on polymorphonuclear leukocyte phagocytosis and oxidant radical production. Chemotherapy. 1995 Sep-Oct;41(5):360-7.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481